Bioavailability of IX-01 Capsule vs Aqueous Dispersion

Phase 1, randomised, open-label trial of cligosiban in premature ejaculation (PE) (3 arms), sponsored by Ixchelsis. Primary endpoints: Relative Bioavailability (Frel) of a Capsule Compared to a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity at 96 hours, Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in the Fed State Compared to the Fasted State, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time… at 96 hours and 9 more. Started May 2014; status: completed.